NCT02373254

Brief Summary

This study is being conducted to evaluate whether NSAIDS are more or less effective in bone healing than opioids in acute fracture pain. Participants will be randomized to one of three groups for first line treatment of pain related to the fracture.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for early_phase_1

Timeline
Completed

Started Jan 2015

Shorter than P25 for early_phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

February 9, 2015

Completed
17 days until next milestone

First Posted

Study publicly available on registry

February 26, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2015

Completed
Last Updated

July 14, 2017

Status Verified

July 1, 2017

Enrollment Period

9 months

First QC Date

February 9, 2015

Last Update Submit

July 11, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • fracture healing as measured by radiographic evaluation

    fracture healing at 12 weeks followup

    12 weeks

Secondary Outcomes (2)

  • pain level improvement as measured by VAS score

    1 week, 2 weeks, 6 weeks, 9 weeks and 12 weeks

  • functional improvement as measured by AAOS score

    1 weeks, 2 weeks 6 weeks, 9 weeks and 12 weeks

Study Arms (3)

Ibuprofen 400 mg

ACTIVE COMPARATOR

Ibuprofen 400 mg po q 8 hours as needed (PRN) for pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.

Drug: Ibuprofen

Ibuprofen 800 mg

ACTIVE COMPARATOR

Ibuprofen 800 mg po q 8 hours PRN pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.

Drug: Ibuprofen

Norco

ACTIVE COMPARATOR

Norco (acetaminophen/hydrocodone) 10/325 mg po q 6 hours PRN pain. If pain is not relieved, physician should be contacted.

Drug: Acetaminophen/hydrocodone

Interventions

Ibuprofen 400 mg and 800 mg

Also known as: Motrin
Ibuprofen 400 mgIbuprofen 800 mg

Norco 5/325 mg and 10/325 mg

Also known as: Norco
Norco

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age \> 18 to \< 60
  • Isolated ankle fracture type SER II
  • Ability to speak and understand English
  • BMI\< 35

You may not qualify if:

  • ASA\>3
  • Previous or acute gastric bleeding
  • Renal insufficiency (Creatinine: \>1.27mg/dl)
  • Liver insufficiency (Child-Pugh-Wert: 10-15)
  • Malignant tumor
  • Rheumatoid arthritis
  • Heart failure (NYHA III-IV)
  • High frequency absolute arrhythmia
  • Patients with known psychiatric illness
  • Coagulopathy
  • Asthma
  • Adults unable to consent
  • Pregnant women
  • Prisoners
  • Workers Comp patient
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California Davis

Sacramento, California, 95817, United States

Location

MeSH Terms

Conditions

Ankle Fractures

Interventions

Ibuprofenoxycodone-acetaminophen

Condition Hierarchy (Ancestors)

Fractures, BoneWounds and InjuriesAnkle InjuriesLeg Injuries

Intervention Hierarchy (Ancestors)

PhenylpropionatesAcids, CarbocyclicCarboxylic AcidsOrganic Chemicals

Study Officials

  • Robert J Steffner, MD

    University of California, Davis

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 9, 2015

First Posted

February 26, 2015

Study Start

January 1, 2015

Primary Completion

October 1, 2015

Study Completion

October 1, 2015

Last Updated

July 14, 2017

Record last verified: 2017-07

Locations